

Table 1 : Clinical and Epidemiological Characteristics of 522 patients with allergic rhinitis, asthma, COPD and COVID-19

Disease	AR	BA	BA and AR	COPD	COVID-19	COVID-19& COPD	COVID-19 & BA
Number of cases (522 Total)	83	69	75	67	78	80	70
Variables							
Symptoms*							
• Fever # (greater than 38.0 C)	2(2.4%)	1(1.4%)	2 (2.7)	4 (6%)	76(97.4%)	79(98.8%)	69 (98.6%)
• Dry cough	8(9.6%)	15(21.7%)	13(17.3%)	22(32.8%)	53(67.9%)	27(33.8%)	42 (60%)
• Cough with sputum	36(43.3%)	51(73.9%)	57(76%)	45(67.2%)	25(32.1%)	53(66.7%)	28(40%)
• Headache €	78(94%)	42(60.9%)	72(96%)	8(11.9%)	7(9%)	5(6.3%)	7(10%)
• Throat pain€	49(59%)	51(73.9%)	55(73.3%)	2(3%)	5(6.4%)	7(8.8%)	6(8.6%)
• Diarrhea #	2(2.4%)	1(1.4%)	1(1.3%)	0(0%)	34(43.6%)	40(50%)	28(40%)
• Runny nose &	49(59%)	12(17.4%)	39(52%)	0(0%)	0(0%)	0(0%)	0(0%)
• Bad breath	60(72.2%)	30(43.5%)	47(62.7%)	0(0%)	0(0%)	0(0%)	5(7.1%)
• Weakness in smell and taste senses #	27(32.5%)	6(8.7%)	28(37.3%)	3(4.5%)	60(76.9%)	53(66.3%)	45(64.3%)
• Hoarseness &	44(53%)	8(11.6%)	32(42.7%)	0(0%)	0(0%)	0(0%)	0(0%)
• Pain in the ears or teeth&	55(66.2%)	3(4.3%)	43(57.3%)	0(0%)	0(0%)	0(0%)	0(0%)
• Shortness of breath #	42(50.6%)	30(43.5%)	46(61.3%)	67(100%)	78(100%)	80(100%)	70(100%)
• Wheezing	10(12%)	24(34.8%)	45(60%)	56(83.6%)	0(0%)	67(83.8%)	53(75.7%)
• Tachypnea	14(16.8%)	24(34.8%)	34(45.3%)	56(83.6%)	67(85.9%)	67(83.8%)	56(80%)
• Swelling around the eyes or nose	20(24.1%)	9(13%)	18(24%)	0(0%)	0(0%)	0(0%)	0(0%)
• Blue color in the lips #	1(1.2%)	0(0%)	6(8%)	22(32.8%)	34(43.6%)	67(83.8%)	14(20%)
• Fatigue	80(96.4%)	63(91.3%)	72(96%)	64(95.5%)	73(93.6%)	72(90%)	66(94.3%)
Symptoms increase with exposure to cold air or dust* €	78(94%)	66(95.7%)	73(97.3%)	0(0%)	0(0%)	0(0%)	14(20%)
Symptoms duration *							
-Persistent	21(25.3%)	3(4.3%)	28(37.3%)	57(85%)	76(97.4%)	80(100%)	69(98.6%)
-Intermittent	62(74.7%)	66(95.7%)	47(62.7%)	10(15%)	2(2.6%)	0(0%)	1(0.4%)

AR= Allergic rhinitis, BA=Bronchial asthma, COPD=Chronic obstructive pulmonary disease , COVID-19= coronavirus disease 2019

*The values are given as the number of patients, with the percentage in parentheses for each group separately .

Indicates significant difference in symptoms of fever, diarrhea, shortness of breath, blue color in the lips, and weakness in smell and taste senses, on comparing all COVID-19 groups to allergic rhinitis, asthma and COPD patients at p<0.05.

& Indicates significant difference in symptoms of hoarseness, runny nose, and pain in the ears or teeth on comparing allergic rhinitis patients, either having asthma or not, to other groups at p<0.05.

€ Indicates significant difference in symptoms of headache, throat pain and increase in symptoms with exposure to cold air or dust, on comparing asthmatic patients, allergic rhinitis patients, and patients with both diseases to other groups at p<0.05.